Aktis Oncology is a biotechnology company focused on discovering and developing transformative therapies for solid cancers using alpha radiotherapy.

Aktis Oncology

Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. 

Bristol-Myers Squibb

EcoR1 Capital

Novartis

Octagon Capital Advisors

TCG Crossover

Vida Ventures

MPM Capital

Cowen Healthcare Investments

NS Investment

Merck

Mirae Asset Venture Investment

MRL Ventures Fund

Aktis Oncology is pleased to announce our participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. Matthew Roden, CEO, will be presenting on September 4th from 10:00 to 10:35 a.m. at the New York Marriott Marquis. 
  
We look forward to sharing our vision for the future of oncology and connecting with industry leaders and investors. 
 
https://lnkd.in/gxU8ZsCq

Today, we celebrate Women's Equality Day and honor the incredible contributions women have made to cancer research and treatment.
 
From Marie Curie's groundbreaking work on radioactivity to Dr. Jane Cooke Wright's pioneering chemotherapy research, women have been at the forefront of oncology breakthroughs for generations. 
 
At Aktis Oncology, we're proud to have talented women driving our mission forward. We remain committed to fostering an inclusive environment where all voices are heard and valued.

#WomensEqualityDay #WomeninSTEM #CancerResearch #JoinUs

At Aktis Oncology, we believe in supporting our community. On Child Protection Day, our team volunteered with GIVING FACTORY DIRECT by Cradles to Crayons to address clothing insecurity affecting 22 million American children.
 
Aktis Oncology proudly matched each donation. 
 
#ChildProtectionDay #GivingBack #cradlestocrayons

Today we are proud to announce the promotions of four exceptional people within our organization. Join us in congratulating:

·  Will Blackwell on his promotion to Director, Chemistry
·  Tatsiana Kosciuk on her promotion to Senior Scientist, Molecular Pharmacology
·  Marci Copeland on her promotion to Principal Scientist, Molecular Pharmacology
·  Wai Lau on his promotion to Director, Lead Discovery
 
We are proud to have such talented individuals as part of our team and look forward to their continued achievements in their new roles. Please join us in celebrating their well-deserved success!
 
#AktisOncology #GreatPlaceToWorkFor #GreatCompanyCulture #Collaboration #Innovation #Growth #Hiring

Celebrating PRIDE together!  
  
Our teams in Boston and RTP recently gathered for a special PRIDE luncheon. We proudly supported LGBTQ+ owned businesses, Basil Tree and Indulge Catering, who provided delicious food for the event. 
  
Thank you to all our employees who joined in this celebration. Together, we support an inclusive workplace for all. 
  
#PrideMonth #Inclusion #LGBTQAllies

In celebration of Asian America and Pacific Islander Heritage Month, we embraced the rich cultures of the Pacific Islands by offering hula lessons for our employees! 
  
It was amazing to see our team members learn the movements and meaningful traditions behind this beautiful Hawaiian dance. The lessons highlighted the storytelling and spiritual aspects of hula. Big mahalo to our Aktis hula instructor, Kelly Williamson Polanco, who was happy to share a part of her family heritage.
  
At Aktis Oncology, we take pride in recognizing the diverse backgrounds and perspectives of our team. Initiatives like this help create a more inclusive workplace where we can learn from each other and have fun. 
  
#AAPIHeritageMonth #DiversityCelebration #EmployeeEngagement #HulaDance

Metric
Company Name	Aktis Oncology
Symbol
MSH ID	COM:AKTISONCOLOGY
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	54
Website	aktisoncology.com
LinkedIn	aktis-oncology
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

AKTI

COM:AKTISONCOLOGY

Aktis Oncology

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue